SYRESpyre Therapeutics, Inc.

$90.61

$14.8252 weeks$108.94

Price

$90.61+435%1Y

1M-12%1Y+435%

Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.

Smart Score

Average

6/10

Value61

Quality33

Momentum71

Growth-

Strongest Momentum, weakest Quality · ranked vs Healthcare peers. The five questions below judge the company on its own terms.

What they do

Spyre Therapeutics, Inc. (NASDAQ: SYRE) is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases. Spyre’s pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations.

In the company’s own words · 10-K filed Feb 19, 2026 · SEC EDGAR

P/E (TTM)-

Market Cap$7.70B

1Y Return+435%

5Y Return-44%

For the full year FY2025, revenue was $0 and net income −$155M.